{"url_path":"/sec/cocp/8-k/2026-07-17/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-17","source_url":"https://www.sec.gov/Archives/edgar/data/1412486/0001493152-26-033662-index.html","accession_number":"0001493152-26-033662","cik":"0001412486","ticker":"COCP","issuer_name":"Cocrystal Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1412486/0001493152-26-033662-index.html","primary_entity_key":"0001412486","primary_entity_name":"Cocrystal Pharma, Inc."},"word_count":359,"has_tables":true,"body_markdown":"**Item\n5.07 Submission of Matters to a Vote of Security Holders.**\n\n \n\nOn\nJuly 14, 2026, the 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) of Cocrystal Pharma, Inc. (the “Company”)\nwas held. At the 2026 Annual Meeting, the Company’s stockholders voted on (i) the election of five members of the Company’s\nBoard of Directors (Proposal 1); (ii) ratification of the appointment of Weinberg & Company as the Company’s independent registered\npublic accounting firm for the fiscal year ending December 31, 2026 (Proposal 2); and (iii) approval of an adjournment of the 2026 Annual\nMeeting to a later date or time, if necessary, to permit further solicitation and vote of proxies if there are not sufficient votes at\nthe time of the 2026 Annual Meeting to approve any of the proposals presented for a vote at the 2026 Annual Meeting (Proposal 3), all\nas described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on May\n27, 2026.\n\n \n\nSet\nforth below are the voting results on each matter submitted to the stockholders at the 2026 Annual Meeting.\n\n \n\nProposal\n1. The Company’s stockholders voted to elect the following five individuals as directors to hold office until the next annual\nmeeting of stockholders and until his or her successor is duly elected and qualified:\n\n \n\nNominee\n \nVotes\nFor\n \nAbstentions\n \nBroker\nNon-Votes\n\nDr.\nRoger Kornberg\n \n6,113,868\n \n392,124\n \n2,860,552\n\nDr.\nPhillip Frost\n \n6,276,012\n \n229,980\n \n2,860,552\n\nMr.\nFred Hassan\n \n6,293,331\n \n212,661\n \n2,860,552\n\nMr.\nRichard C. Pfenniger, Jr.\n \n5,964,606\n \n541,386\n \n2,860,552\n\nMr.\nSteven Rubin\n \n5,914,522\n \n591,470\n \n2,860,552\n\n \n\nProposal\n2. The Company’s stockholders voted to ratify the appointment of Weinberg & Company as the Company’s independent\nregistered public accounting firm for the fiscal year ending December 31, 2026.\n\n \n\nVotes\nFor\n \nVotes\nAgainst\n \nAbstentions\n\n9,181,034\n \n174,923\n \n10,587\n\n \n\nAs\nthere were sufficient votes to approve Proposals 1 and 2, Proposal 3 was moot.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**Cocrystal\nPharma, Inc.**\n\n \n \n \n\nDate:\nJuly 17, 2026\nBy:\n*/s/\nJames Martin*\n\n \nName:\nJames\nMartin\n\n \nTitle:\nChief\nFinancial Officer"}